Raju Prasad
1.2K posts
@rprasad5
CFO at CRISPR | Author of Building Breakthoughs: On the Frontier of Medical Innovation (order below). Opinions are my own. "Be curious, not judgmental”.
Today, we shared a clinical update on zugo-cel (formerly known as CTX112™), reflecting continued progress across autoimmune disease and hematologic malignancies. Learn more here: bit.ly/4asQ0ub
We are pleased to share new data from multiple studies of our gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia at the 67th ASH Annual Meeting this weekend. Learn more: news.vrtx.com/news-releases/… #ASH25
We announced positive late-breaking Phase 1 data for CTX310 at #AHA25, demonstrating deep and durable ANGPTL3 editing with lowering of triglyceride and lipid levels, published in @NEJM. A major milestone for our in vivo gene-editing platform. bit.ly/4nII4I4
We're proud to be named on @TIME's Most Influential Companies of 2025 list – a recognition for our work toward bringing genetic medicines to people suffering from serious diseases on a global scale. Congrats to all the #TIME100Companies! time.com/collections/ti…
Today, we announced a collaboration with Sirius Tx to co-develop SRSD107, a next generation, long-acting Factor XI siRNA for the treatment of thromboembolic disorders. This will expand our cardiovascular portfolio and broaden our therapeutic toolkit. bit.ly/4kjPEaS
Today, we reported our first quarter earnings results and announced positive top-line data from our Phase 1 clinical trial of CTX310™ targeting ANGPTL3. Read more about our recent highlights and business update: bit.ly/3GG89rv #CRSP #CRISPRTX
We are pleased to announce that we’ve completed the submission of our Biologics License Applications (BLAs) to the U.S. FDA for our potential treatment for sickle cell disease and beta thalassemia. Learn more: bit.ly/3K2P7cR
